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We demonstrate the inhibition of the native phosphatase activity of a cold active alkaline phospha-
tase from Vibrio (VAP) (IC50 of 44 ± 4 (n = 4) lM at pH 7.0 after a 30 min preincubation) by a speciﬁc
b-lactam compound (only by imipenem, and not by ertapenem, meropenem, ampicillin or penicillin
G). The homologous scaffold was detected by an in silico analysis that established the spatial and
electrostatic congruence of the active site of a Class B2 CphA metallo-b-lactamase from Aeromonas
hydrophila to the active site of VAP. The tested b-lactam compounds did not inhibit Escherichia coli
or shrimp alkaline phosphatase, which could be ascribed to the lower congruence indicated by
CLASP. There was no discernible b-lactamase activity in the tested alkaline phosphatases. This is
the ﬁrst time a scaffold recognizing imipenem in an alkaline phosphatase (VAP) has been
demonstrated.
 2012 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction
Bacteria develop resistance to b-lactam antibiotics using various
mechanisms [1], among which production of enzymes is the most
common [2,3]. The Ambler classiﬁcation has four classes of b-lacta-
mases – Classes A, C, D have a nucleophilic serine at the active site,
while Class B b-lactamases are metallo-enzymes requiring zinc for
their activity [4,5]. Metallo-b-lactamases (MBLs) can hydrolyze
most classes of b-lactam compounds except monobactams [6,7],
and are not susceptible to therapeutic b-lactamase inhibitors mak-
ing them a major medical concern [8–10]. MBLs have been dividedchemical Societies. Published by E
line phosphatase; VAP, Vibrio
atase; SAP, shrimp alkaline
Active Site Prediction; pNPP,
e; APBS, adaptive Poisson–
borty).into three subgroups – B1, B2, and B3 – based on sequence similar-
ity [11–13]. Enzymes of Class B2 MBL are catalytically active with
one Zn2+ ion and selectively hydrolyze carbapenems, whereas en-
zymes of Classes B1 and B3 typically require two Zn2+ ions and
can also hydrolyze penicillins and cephalosporins [7].
Previously, we have established a computational method (Cata-
Lytic Active Site Prediction – CLASP) based on spatial and electro-
static properties for the detection of active sites [14]. CLASP was
applied to the family of alkaline phosphatases (AP), one of the
widely studied promiscuous enzymes [15]. This led previously to
the discovery of a serine protease scaffold in APs [14].
In the present work, we probed for a relationship between MBLs
and APs by searching for the MBL active site motif in the AP protein
structures. CLASP analysis indicated a highly congruent match with
an MBL active site motif [16] in a cold-active Vibrio AP (VAP) [17].
We show for the ﬁrst time a scaffold homologous to the Class B2
CphA metallo-b-lactamase from Aeromonas hydrophila in an AP
(VAP) using a computational method based on the spatial and
electrostatic congruence of active site residues, and validate it bylsevier B.V. All rights reserved.
S. Chakraborty et al. / FEBS Letters 586 (2012) 3710–3715 3711demonstrating the inhibition of the native phosphatase activity of
VAP by imipenem through in vitro experiments.
To the best of our knowledge, the only relationship shown so far
between MBLs and APs is the hydrolysis of benzylpenicillin by a
metal coordination complex devoid of protein that functionally
mimics APs [18–20]. Renal dehydropeptidase, another zinc-depen-
dent metallo-enzyme, is known to possess the ability to hydrolyze
imipenem [21], This highlights a situation quite similar to our cur-
rent ﬁnding, where the scaffold recognizes imipenem and not
other tested b-lactam compounds.
2. Materials and methods
2.1. Materials
Adaptive Poisson–Boltzmann Solver (APBS) and PDB2PQR pack-
ages were used to calculate the electrostatic potentials of all the
atoms in the protein [22,23]. The APBS parameters were set as de-
scribed previously in [14]. APBS writes out the electrostatic poten-
tial in dimensionless units of kT/e where k is Boltzmann’s constant,
T is the temperature in K and e is the charge of an electron. All pro-
tein structures were rendered by PyMol (http://www.pymol.org/).
We extensively integrated and used the freely available BioPerl
[24] modules and Emboss [25] tools.
2.2. Methodology
The theoretical foundation for CLASP is the non-triviality of the
congruence in cognate pairs seen across various structures of the
same superfamily (Supplementary Table 1 shows the congruence
in the serine-b-lactamase superfamily [26]), and is thus an innate
property of the family. Finite difference Poisson–Boltzmann (FDPB)
electrostatics was used to compute electrostatic potential from
charge interactions in proteins by tools that implement a fast
numerical approximation of solutions to the linearized Poisson–
Boltzmann equation [22,27–29]. This invariance in the electro-
static potential difference across structures that have been solved
independently over many years speaks highly of the reliability of
the APBS/PDB2PQR implementation.
CLASP starts with a motif consisting of N residues from the cat-
alytic site of the reference protein (a Class B2 MBL in this case) (Eq.
(1)). Each position of the motif has a set of amino acids speciﬁed to
allow for stereochemically equivalent matches at that particular
position (Eq. (2)).
Uresidues ¼ fR1;R2 . . .RNg; ð1Þ
Ugroups ¼ fGROUP1;GROUP2 . . .GROUPNg; ð2Þ
All sets of N residues (Eq. (3)), with the constraint that each res-
idue – amino acid type of ri (Eq. (4)) belongs to GROUPi (Eq. (2))
should be from the group speciﬁed – are obtained in the query pro-
teins (alkaline phosphatases in this case) using an exhaustive
search procedure similar to the one used in SPASM [30]. The pair-
wise distances and electrostatic potential differences are computed
for each match in the query protein, and compared with the refer-
ence motif generating the CLASP score. This scores leads to an
ordering of the matches (Eq. (3)), where M1 represents the required
homologous scaffold in the query protein.
macthesUsorted¼fM1;M2;...;MKg; ScoreM1<ScoreM2;ScoreM2<ScoreM3;... ð3Þ
Mi¼fr1;r2;...;rNg ð4Þ
The CLASP score consolidates the distance and the electrostatic
potential difference scores, and reﬂects the likelihood that the
activity in the reference protein exists in the query protein. The
distance scores are normalized to ensure that the same pairwise
distance deviation is more signiﬁcant when the reference distanceis less (a deviation of 1 Å is more signiﬁcant if the distance between
two residues is 3 Å, than if the distance between them is 6 Å). In
order to score electrostatic potential differences, we ignore devia-
tions if the electrostatic potential differences in the cognate pair in
the query and the reference residue pair are both close to zero.
2.3. Enzymes and substrates
ECAP was purchased from M.P. Biomedicals and SAP from Sig-
ma–Aldrich. VAP was prepared as described previously [31].
Ertapenem was from MSD, meropenem from AstraZeneca and imi-
penemwas fromMSD and Sigma–Aldrich. Ampicillin and penicillin
G came from HiMedia, while para-nitophenylphosphate (pNPP)
was from Sigma–Aldrich.
2.4. AP assay – and inhibition using b-lactam antibiotics
AP (19.1 nM ECAP/2.3 nM SAP) was preincubated with b-lactam
antibiotic (2–50 lM ampicillin/penicillin G) for 2 min at room tem-
perature in 50 mM ammonium bicarbonate buffer prior to addition
of substrate p-nitrophenylphosphate (0.1 mM pNPP). The reaction
was then monitored at 405 nm (e = 18,000 M1 cm1) for 10 min
at 10 s intervals using the Tecan M200 plate reader. Pre-incuba-
tions of VAP (0.5–1.0 lM) with ampicillin (500 lM), penicillin G
or imipenem, meropenem and ertapenem (up to 240 lM) were
performed on ice in 50 mM MOPS, pH 7.0, generally for 30 min.
The hydrolysis of p-nitrophenyl phosphate (3 mM) by VAP (5–
10 nM ﬁnal concentration) was subsequently followed at 410 nm
in 0.1 M CAPS, 1.0 mM MgCl2 and pH 9.8 at 10 C
(e = 18,500 M1 cm1).3. Results
We used the MBL motif – Asp120/Cys221/His263 – the Zn li-
gands from a Class B2 CphA MBL protein from A. hydrophila (PDB
id: 3F9O) to query alkaline phosphatases (APs). The standard Class
B b-lactamase (BBL) numbering has been adopted for easy compar-
isons of the sequences of these enzymes [12]. While searching for
matches, Cys221 can be matched with either Cys, Ser or His to
accommodate the variability seen in various MBLs [7]. Along with
three APs – Escherichia coli AP (ECAP), shrimp AP (SAP) and Vibrio
alkaline phosphatase (VAP) – we chose MBLs from each of the
three classes for querying with the MBL active site motif.
The predicted residues in Class B1 and B3 proteins were always
in the active site of the protein responsible for the native MBL
activity (Table 1). The distances and electrostatic potential differ-
ence between cognate pairs of residues were similar, and were re-
ﬂected by the CLASP scores.
All APs contain three metal ion binding sites – M1, M2 and M3.
In ECAP, the sites M1 and M2 bind zinc ions, while M3 binds a
magnesium ion (Fig. 1a). In SAP all binding sites preferably bind
zinc ions (Fig. 1b). Of the metal binding sites in VAP, M1 and M2
bind zinc ions while M3 binds a magnesium ion (Fig. 1c). The pre-
dicted residues in ECAP and SAP coincided with M2, but there is
one predicted residue which does not ligand any metal ion in the
native ECAP and SAP enzymes (Table 1).
On the other hand, all three predicted residues for VAP coin-
cided with the M1 binding site. Fig. 2a shows the superimposed
proteins based on the partial matches (Asp/120/OD1, Cys/221/SG,
His/263/ND1 – PDBid: 3F9O) and (Asp/273/OD1, His/277/ND1,
His/465/ND1 – PDBid: 3E2D) respectively. The distances and elec-
trostatic potential difference between pairwise residues are shown
in Fig. 2b and c, respectively. The CLASP scores suggested that VAP
had the best matching scaffold with the MBL template, a fact
strengthened by the fact that this predicted MBL-like scaffold
Table 1
Predicted residues, pairwise distances and electrostatic potential differences in MBLs and APs.
PDB PR PD D
a b c ab ac bc ab ac bc Score
3F9O(B2) ASP120(z2) CYS221(z2) HIS263(z2) 234.7 104.1 130.6 3.7 6.5 5.8 0
1ZNB(B1) ASP103(z2) CYS181(z2) HIS223(z2) 203.2 126 77.2 1.1 0.6 0.6 1.2
3FCZ(B1) ASP120(z2) CYS221(z2) HIS263(z2) 206.4 132.8 73.6 0.6 0.1 0.1 0.5
1DD6(B1) ASP81(z2) CYS158(z2) HIS139(z1) 180.2 83.3 96.9 0.6 1 1.5 1.4
1JT1(B3) ASP120(z2) HIS121(z2) HIS118(z1) 310.2 188.3 121.9 0.5 1.4 0 0.9
1SML(B3) ASP184(X) SER83(X) HIS89(z1) 133.8 77.4 56.4 0.4 0.3 1.2 0.8
3LVZ(B3) ASP70(X) HIS106(z2) HIS101(z1) 135.4 41.3 94.1 1.6 0.1 0.4 1.2
1ALK(ECAP) ASP369(M2) HIS370(M2) HIS86(X) 191.6 36.6 155 0.5 1.1 0.4 0.9
1K7H(SAP) ASP356(M2) HIS357(M2) HIS359(X) 139.8 58.5 81.3 0.2 0.6 1.3 0.9
3E2D(VAP) ASP273(M1) HIS277(M1) HIS465(M1) 292.5 181 111.4 1.1 1.5 0.5 0.4
1A0 J(Trypsin) ASP102 CYS58 HIS57 180.7 123.4 57.3 2.9 3.1 0.9 3.4
We used the motif (Asp120/Cys221/His263) from a Class B2 CphA MBL from Aeromonas hydrophila (PDBid: 3F9O). The distances are speciﬁed in the reference protein (PDB id:
3F9O) in Å. For the remaining, we show the deviation from the reference value. Electrostatic potential differences are in units of kT/e (k is Boltzmann’s constant, T is the
temperature in K and e is the charge of an electron). They are absolute values and not shown as deviations. If the residues ligand a zinc ion, it is mentioned according to its zinc
binding site in MBLs (z1 or z2) Unliganded residues are mentioned as (X). PR = predicted residues, PD = electrostatic potential difference, D = Distance.
Fig. 1. The active sites for alkaline phosphatases from E. coli (ECAP), shrimp (SAP) and Vibrio sp. (VAP), all consisting of three metal binding sites – M1 in shades of red, M2 in
shades of green and M3 in shades of blue. (a) ECAP (PDB id: 1ALK) – M1 (Asp327, His331, His412) binds a zincion, M2 (Asp51, Ser102, Asp369, His370) binds another zincion,
while M3 (Asp153, Thr155, Glu322) binds a magnesium ion. The MBL active site motif identiﬁes Asp369 and His370 from M2 as residues that might be responsible for MBL
activity. The third predicted residue does not ligand a metal. (b) SAP (PDB id: 1K7H) – M1 (Asp315, His319, His432), M2 (Asp37, Ser86, Asp356, His357), and M3 (Asp37,
His149, Thr151, Glu130) all bind zinc ions. The MBL active site motif identiﬁes Asp356 and His357 from M2 as residues that might be responsible for MBL activity. The third
predicted residue does not ligand a metal. (c) VAP (PDB id: 3E2D) – M1 (Asp273, His277, His465) binds a zincion, M2 (Ser65, Asp315, His316) in red binds another zincion,
while M3 (Asp12, His116, Thr118, Glu268) in green binds either a zinc or a magnesium ion. The MBL active site motif identiﬁes all the residues in M1 as those that might be
responsible for MBL activity, unlike in ECAP and SAP where the match is partial (one residue does not ligand any metal ion).
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in silico prediction by in vitro experiments.
3.1. In vitro experiments
CLASP analysis showing that VAP has an MBL-like scaffold has
been vindicated by the inhibition of its phosphatase activity by
imipenem with an IC50 of 44 ± 4 (n = 4) lM at pH 7.0. Supplemen-
tary Fig. 1 shows the concentration dependence of imipenem inhi-
bition of VAP. The inhibition was time dependent reaching about
98% in 30 min on ice at 1.2 mM and 95% at 0.24 mM. This indicated
that it was an irreversible covalent type of inhibition rather than a
non-covalent equilibrium type of binding. This was tested by tak-
ing a sample of fully inhibited VAP and adding penicillinase from
Bacillus cereus (Sigma–Aldrich) to remove any soluble imipenem.
No VAP activity returned as would be expected if the inhibitor
could freely dissociate from the enzyme. To check if the imipenem
was hydrolyzed, we added a fresh aliquot of VAP back and found
that it remained active (data not shown). VAP did not hydrolyse
imipenem in a parallel assay with the penicillinase from B. cereus
(data not shown). Ertapenem, meropenem, ampicillin or penicillin G
did not have any effect on the phosphatase activity of VAP.
In vitro experiments, even with prolonged incubations, failed to
detect any b-lactamase activity above the metal-ion catalyzed
background in ECAP or SAP. Furthermore, even high concentrationsof ertapenem, meropenem, ampicillin or penicillin G did not inhibit
their native phosphatase activity. This could be ascribed to the
lower congruence of the MBL active site with these APs, especially
the fact that the predicted site in the latter enzymes has residues
that do not ligand any metal ion (His86 for ECAP, and His359 for
SAP). Microbiological assays, which are not subject to the limita-
tion of microiodometric assays regarding the amount of b-lactam
antibiotic that can be used, also could not detect any discernible
activity.
4. Discussion
Electrostatic interactions determine various properties of bio-
molecules such as catalytic activity, ligand binding, structure and
stability [32]. We have established a computational method
(CLASP) based on spatial and electrostatic properties for detection
of active sites [14]. In the current work, CLASP detected a signiﬁ-
cant likelihood for the presence of a Class B2 MBL like scaffold
[16] in a cold active AP (VAP) [17]. The spatial and electrostatic
similarity between the MBL scaffold in the active site of the VAP
(Fig. 1) is highlighted in Table 1 and Fig. 2.
This in silico prediction was validated by the inhibition of the
native phosphatase activity of VAP by imipenem (whereas ertape-
nem, meropenem, ampicillin and penicillin G did not result in any
inhibition). It should be noted that Class B2 MBLs are strict
Fig. 2. Superimposition of active sites of MBL and VAP based on the active site match – (Asp/120/OD1, Cys/221/SG, His/263/ND1 – PDBid: 3F9O) and (Asp/273/OD1, His/277/
ND1, His/465/ND1 – PDBid: 3E2D) respectively (a) Superimposition of both proteins: MBL (PDBid: 3F9O) is in blue, and VAP (PDBid: 3E2D) is in green. After the
superimposition, all three atoms in both the proteins lie on the same plane (Z = 0 for all atoms), such that Asp120/OD1 and Asp273/OD1 (colored in black) lie on the
coordinate Centre, His263/ND1 and His277/ND1 lie on the X–Y plane (Y = 0). The active site residues of MBL are in red, while the residues of VAP are in yellow. (b) Distances
between pairs of residues in the matches. Distances are in Å. (c) Electrostatic potential difference between pairs of residues in the matches. See Section 2 for units of
electrostatic potential.
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cephalosporins. The trans orientation of the hydrogens at carbon 5
and 6 in the carbapenems, as compared to the cis orientation in
penicillins and cephalosporins, is hypothesized to be the reason
for this difference [33]. Similarly, the possible explanation for the
observed difference of inhibition of VAP by imipenem and the
other two tested carbapenems (ertapenem and meropenem) might
be the presence of a methyl group at the C1 position in meropenem
and ertapenem [33]. As noted below, this additional methyl group
also seems to be involved in the resistance of ertapenem and
meropenem to the hydrolytic activity of renal dehydropeptidase.
We have superimposed imipenem (from PDBid: 1BT5) over ertape-
nem (from PDBid: 3M6B) and meropenem (from PDBid:1H8Y)
(Supplementary Fig. 2a and b, respectively) to demonstrate this
difference. These b-lactam compounds failed to inhibit the native
phosphatase activity in both E. coli AP (ECAP) and shrimp AP
(SAP), and can be ascribed to the lower congruence with the MBL
active site as indicated by CLASP analysis.
Renal dehydropeptidase is known to possess the ability to
hydrolyze imipenem [21]. The renal dehydropeptidase inhibitor
cilastatin is co-administered with imipenem to increase its
effectiveness in inhibiting the MBL, thus reﬂecting structuralsimilarities in the active sites in the absence of any signiﬁcant
sequence homology [34]. The likeness of the current situation,
wherein only imipenem inhibits the native activity in VAP, to the
case of the hydrolysis of only imipenem by renal dehydropeptidase
is striking.
In vitro experiments failed to detect any MBL activity in ECAP,
SAP or VAP. One needs to be careful in ascertaining a weak MBL
activity through long periods of incubation since it is known that
ions catalyze the hydrolysis of penicillin [35]. The stability of b-lac-
tam compounds in the reaction buffer is of paramount importance
[36]. An additional hurdle in determining MBL activity in APs is
due to the fact that b-lactam antibiotics are unstable at the opti-
mum pH for phosphatase catalysis (>8) [36].
The only known relationship experimentally conﬁrmed so far
between MBLs and APs is that a functional complex that mimics
AP also hydrolyzes benzylpenicillin [18–20]. The MBL like scaffold
reported in APs in the current work has helped in drawing another
parallel between the AP and MBL superfamilies, which have anal-
ogous catalytic activities [37,38] (Supplementary Fig. 3).
The ongoing evolution in MBLs is embodied by the isolation of
better enzyme variants from clinical isolates [39]. It has also been
shown that it is possible to confer MBL activity to glyoxalase II,
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lase II scaffold [40]. Interestingly, a later study detected MBL activ-
ity in mitochondrial glyoxalase II from Arabidopsis thaliana [41]. It
is a distinct possibility that APs might evolve to work as MBLs, as
improved variants of both APs [42] and MBLs [43] have been gen-
erated under controlled laboratory conditions. The fact that APs
from different organisms exhibit various promiscuous activities
has been previously observed [44,45]. The natural evolution of
APs with enhanced MBL activity raises concerns with respect to
further bacterial resistance since these APs are not to be considered
as evolutionary dead end proteins [46].
As a future plan, we intend to perform random mutagenesis of
APs and select clones which have gained b-lactamase activity.
The difﬁculty of this approach can be assessed from the lack
of MBL activity in CphA2 protein from the hyperthermophile
Aquifex aeolicus, although it has all the conserved motifs of the
MBL superfamily and a non-trivial identity with the A. hydro-
phila Class B2 CphA MBL [47]. Similarly, few directed evolution
experiments have reported success in enhancing deacylation in
penicillin binding proteins [48,49], the additional catalytic step
that the related serine b-lactamases use to hydrolyze b-lactams
[50].
In conclusion, for the ﬁrst time, we demonstrate a scaffold rec-
ognizing imipenem in an AP (VAP) through in vitro experiments, a
ﬁnding based on an in silico analysis that detected a scaffold
homologous to an MBL active site in VAP. Such a computational
method, based on the spatial and electrostatic congruence of active
site residues, reveals relationships that often escape detection by
sequence alignment or global structure alignment methods. The
possibility of the natural evolution of APs to acquire true MBL
activity in the wake of the existing MBL-like scaffold could lead
to further bacterial resistance.Acknowledgements
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